CSTL
CASTLE BIOSCIENCES INC
Next earnings Aug 3, 2026 · consensus $-0.41 EPS, $88.0M rev
Last earnings +0.6% on 2026-05-06
$24.30
▲ +6.07%$24.30▲ +28.91%
over 1Y
L $14.65EODHDH $43.04
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.1%
1W+14.6%
1M+14.3%
3M+3.3%
YTD-36.9%
1Y+28.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.23x); but unprofitable (net margin -7.0%).
Revenue (FY2025) $344M · FY2025
CASTLE BIOSCIENCES INC shows $344M in FY2025 revenue (+3.7% YoY), a -7.0% net margin, and -5.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $94.1M | $137M | $220M | $332M | $344M |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.1M | -$72.9M | -$68.0M | $8.67M | -$42.8M |
| Net income | -$31.3M | -$67.1M | -$57.5M | $18.2M | -$24.2M |
| Diluted EPS | -$1.24 | -$2.58 | -$2.14 | $0.62 | -$0.83 |
| Net margin | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$616M
EV / EBITDA—
EV / Sales1.8
EV / FCF21.7
P / FCF25.5
PEG (trailing)—
Earnings yield-3.3%
FCF yield3.9%
Quality & risk
ROIC (est.)-7.0%
Free cash flow$28.3M
Total debt$10.1M
Net cash$107M
Altman Z-Score4.44 safe
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-16open ↗4Period ending 2026-06-012026-06-03open ↗144Filing2026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗4Period ending 2026-05-282026-06-01open ↗
Frequently asked
- Is CASTLE BIOSCIENCES INC (CSTL) a buy?
- CSTL currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.23x); but unprofitable (net margin -7.0%).
- What is CASTLE BIOSCIENCES INC's quality score?
- CSTL scores 47.70588235294117/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001447362, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 7:02:41 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.